- Home
- SUPN
as 10-24-2025 3:52pm EST
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 2.6B | IPO Year: | 2012 |
| Target Price: | $62.67 | AVG Volume (30 days): | 725.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.14 | EPS Growth: | 1411.53 |
| 52 Week Low/High: | $29.16 - $53.28 | Next Earning Date: | 11-04-2025 |
| Revenue: | $665,125,000 | Revenue Growth: | 5.55% |
| Revenue Growth (this year): | 7.31% | Revenue Growth (next year): | 21.87% |
Stock Insider Trading Activity of Supernus Pharmaceuticals Inc. (SUPN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Khattar Jack A. | SUPN | President, CEO | Oct 9 '25 | Sell | $51.00 | 59,900 | $3,029,336.39 | 1,206,578 | |
| NEWHALL CHARLES W III | SUPN | Director | Oct 9 '25 | Sell | $51.14 | 25,000 | $1,269,234.00 | 105,844 | |
| Khattar Jack A. | SUPN | President, CEO | Oct 2 '25 | Sell | $48.06 | 1,904 | $91,506.24 | 1,206,578 | |
| Khattar Jack A. | SUPN | President, CEO | Oct 1 '25 | Sell | $48.07 | 40,173 | $1,931,116.11 | 1,206,578 | |
| Khattar Jack A. | SUPN | President, CEO | Sep 30 '25 | Sell | $48.25 | 8,588 | $414,371.00 | 1,206,578 | |
| Khattar Jack A. | SUPN | President, CEO | Sep 29 '25 | Sell | $48.02 | 10,235 | $491,484.70 | 1,206,578 | |
| Khattar Jack A. | SUPN | President, CEO | Sep 23 '25 | Sell | $47.23 | 29,513 | $1,393,898.99 | 1,206,578 | |
| Khattar Jack A. | SUPN | President, CEO | Sep 22 '25 | Sell | $47.02 | 16,587 | $779,920.74 | 1,206,578 | |
| Mottola Frank | SUPN | SVP, Chief Tech. Ops. Officer | Sep 12 '25 | Sell | $45.87 | 5,000 | $229,350.00 | 15,496 | |
| Khattar Jack A. | SUPN | President, CEO | Sep 8 '25 | Sell | $46.29 | 6,322 | $292,645.38 | 1,206,578 |
Latest Supernus Pharmaceuticals Inc. News
SUPN Breaking Stock News: Dive into SUPN Ticker-Specific Updates for Smart Investing
StockStory
7 days ago
3 Stocks Under $50 We Steer Clear Of
MT Newswires
25 days ago
Supernus Pharmaceuticals Insider Sold Shares Worth $1,931,116, According to a Recent SEC Filing
Simply Wall St.
25 days ago
Supernus Pharmaceuticals (SUPN): Is the Current Share Price a Fair Reflection of Its True Valuation?
MT Newswires
a month ago
Supernus Pharmaceuticals Insider Sold Shares Worth $491,485, According to a Recent SEC Filing
Simply Wall St.
2 months ago
Can Mixed Fundamentals Have A Negative Impact on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Current Share Price Momentum?
StockStory
2 months ago
1 Cash-Producing Stock to Research Further and 2 We Brush Off
Insider Monkey
2 months ago
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio
StockStory
4 months ago
Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions
Compare SUPN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SUPN Supernus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.